Stock market recommendations: According to Mehul Kothari, DVP – Technical Research, Anand Rathi Shares and Stock Brokers, Tube Investments, Godrej Agrovet Ltd, and Astrazeneca Pharma are the top stock picks for today:
TUBEINVEST: BUY Near ₹2850 | Stop Loss: ₹2600 | Target: ₹3350
The stock was highly oversold but has started to outperform in the last few days. Most importantly, a change of trend has been confirmed on the short-term charts. Today, a breakout was observed with strong volumes, reinforcing the strength of this move.
Previously, a breakdown occurred around ₹3200–₹3300, and the stock now appears to be preparing for a retest of that zone.
Thus, traders are advised to buy TUBEINVEST in the range of ₹2750–₹2850, with a stop-loss at ₹2600 on a closing basis, for an upside target of ₹3350 in the coming 1–3 months.
GODREJAGRO: BUY ABOVE ₹750 | Stop Loss: ₹700 | Target: ₹850
The stock has significantly outperformed the broader markets and has been consolidating in a range for the past 5–6 months. Based on the current structure, a breakout from this range appears imminent.
With limited downside risk from current levels, traders are advised to buy GODREJAGRO ABOVE ₹750, with a strict stop-loss at ₹700 on a closing basis, for an upside target of ₹850 in the coming 1–3 months.
ASTRAZEN: BUY Near ₹7800 | Stop Loss: ₹7500 | Target: ₹8400
The stock exhibits a structure similar to GODREJAGRO, but even stronger. Today, it delivered a major range breakout, and that too near its lifetime high.
Additionally, RSI has confirmed a breakout, and ADX (14) crossing 28 signals a strengthening trend, indicating the potential for a sharp upside move.
Thus, traders are advised to buy ASTRAZEN in the range of ₹7750–₹7850, with a stop-loss at ₹7500 on a closing basis, for an upside target of ₹8400 in the coming 1–3 months.
Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.
